Market Place
Sourcing Support
Rani Therapeutics Reports Q3 2024 Results & Corporate Update
14 Nov 2024 //
GLOBENEWSWIRE
Rani Therapeutics to Participate in Upcoming Investor Conferences
07 Nov 2024 //
GLOBENEWSWIRE
Rani Therapeutics Reveals New Data On GLP-1 Delivery Method
17 Oct 2024 //
GLOBENEWSWIRE
Rani Therapeutics Announces $10 Million Registered Direct Offering
15 Oct 2024 //
GLOBENEWSWIRE
Rani Therapeutics To Participate In 2024 Maxim Healthcare Summit
08 Oct 2024 //
GLOBENEWSWIRE
Rani Therapeutics to Participate in September Investor Conferences
03 Sep 2024 //
GLOBENEWSWIRE
Rani Therapeutics Reports Q2 2024 Results And Corporate Update
06 Aug 2024 //
GLOBENEWSWIRE
Rani Therapeutics to Participate in August Investor Conferences
29 Jul 2024 //
GLOBENEWSWIRE
Rani Therapeutics Prices $10.0M Registered Direct Offering
22 Jul 2024 //
GLOBENEWSWIRE
Rani, ProGen Partner To Co-Develop & Commercialize Oral Obesity Treatment
24 Jun 2024 //
CONTRACT PHARMA
Rani Therapeutics to Participate in May Investor Conferences
14 May 2024 //
GLOBENEWSWIRE
Rani Oral Biosimilar Ustekinumab Data At DDW 2024
09 May 2024 //
GLOBENEWSWIRE
Rani Therapeutics Reports Q1 2024 Results, Corporate Update
06 May 2024 //
GLOBENEWSWIRE
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
15 Mar 2024 //
GLOBENEWSWIRE
Rani Therapeutics Announces Positive Topline Results from Ph 1 Study of RT-111
05 Feb 2024 //
GLOBENEWSWIRE
Rani Announces Data on Transenteric Delivery of GLP-1 Incretin Triagonist
14 Dec 2023 //
GLOBENEWSWIRE
Rani Therapeutics Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Rani and Sangamo jettison staff, assets to keep afloat next year
02 Nov 2023 //
FIERCE BIOTECH
Rani Therapeutics Announces Strategic Program Prioritization
01 Nov 2023 //
GLOBENEWSWIRE
The RaniPill Capsule, Rani Therapeutics™ Platform, was Well-Tolerated in 60-Day
25 Oct 2023 //
GLOBENEWSWIRE
Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody
19 Oct 2023 //
GLOBENEWSWIRE
Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting
12 Oct 2023 //
GLOBENEWSWIRE
Rani Therapeutics Initiates Phase 1 Study of RT-111
18 Sep 2023 //
GLOBENEWSWIRE
Rani Announces Successful Drug Delivery of High-Capacity Pill in Studies
07 Sep 2023 //
GLOBENEWSWIRE
Rani Therapeutics to Participate in September Investor Conferences
06 Sep 2023 //
GLOBENEWSWIRE
Rani Therapeutics Reports Second Quarter 2023 Financial Results
11 Aug 2023 //
GLOBENEWSWIRE
Rani Therapeutics to Participate in August Investor Conferences
04 Aug 2023 //
GLOBENEWSWIRE
Rani Therapeutics™ Presentation On Oral Delivery of PTH for Osteoporosis Na
21 Jun 2023 //
GLOBENEWSWIRE
Rani Therapeutics’ oral ‘robotic pill’ delivers injection trans-enterically
19 Jun 2023 //
PHARMAFILE
Rani Announces Acceptance of Abstract of Oral Delivery of GLP-1 Agonist
08 Jun 2023 //
GLOBENEWSWIRE
Rani Therapeutics expands biologics partnership with Korean firm Celltrion
07 Jun 2023 //
BIOSPECTRUM ASIA
Rani and Celltrion Expand Partnership to Include Adalimumab Biosimilar
05 Jun 2023 //
GLOBENEWSWIRE
Rani Therapeutics to Present at the Jefferies Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
Rani Announces Acceptance of Abstracts for Presentation at ENDO Conference
31 May 2023 //
GLOBENEWSWIRE
Rani Therapeutics Appoints Kate McKinley as Chief Business Officer
24 May 2023 //
GLOBENEWSWIRE
Rani Therapeutics Reports 1Q 2023 Financial Results; Provides Corporate Update
10 May 2023 //
GLOBENEWSWIRE
Rani Therapeutics to Participate in the H.C. Wainwright Conference at NASDAQ
25 Apr 2023 //
GLOBENEWSWIRE
Rani Therapeutics to Present at the 22nd Annual Needham Healthcare Conference
11 Apr 2023 //
GLOBENEWSWIRE
Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
22 Mar 2023 //
GLOBENEWSWIRE
Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
16 Mar 2023 //
GLOBENEWSWIRE
Celltrion signs up to support oral biosimilar of J&J’s Stelara
10 Jan 2023 //
FIERCEPHARMA
Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA
05 Jan 2023 //
GLOBENEWSWIRE
Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Ph1 Study
06 Dec 2022 //
GLOBENEWSWIRE
Rani Therapeutics to Present at the Stifel Healthcare Conference
09 Nov 2022 //
GLOBENEWSWIRE
Rani Announces New RT-111 Development Program and Provides Corporate Update
24 Oct 2022 //
GLOBENEWSWIRE
Rani Therapeutics to Present at the H.C.Wainwright 24th Annual Global Investment
06 Sep 2022 //
GLOBENEWSWIRE
Rani Therapeutics Announces Termination of Public Offering of Class A
11 Aug 2022 //
GLOBENEWSWIRE
Rani Therapeutics Announces Positive Topline Results from Ph1 Study of RT-102
10 Aug 2022 //
GLOBENEWSWIRE
Rani Therapeutics Reports Q2 Financial Results; Provides Corporate Update
10 Aug 2022 //
GLOBENEWSWIRE
Rani Therapeutics Announces Proposed Public Offering of Class A Common Stock
10 Aug 2022 //
GLOBENEWSWIRE
Rani Tx Enters into $45 Million Loan Agreement to Support Ongoing RaniPill
08 Aug 2022 //
GLOBENEWSWIRE
Rani Therapeutics (NASDAQ:RANI) Shares Gap Up to $11.25
21 Jun 2022 //
DEFENSEWORLD
Rani Therapeutics Reports First Quarter 2022 Financial Results
11 May 2022 //
GLOBENEWSWIRE
Rani Therapeutics to Present at Upcoming Investor Conferences
03 May 2022 //
GLOBENEWSWIRE
Rani Tx to Present at the 21st Annual Needham Virtual Healthcare Conference
07 Apr 2022 //
GLOBENEWSWIRE
Rani Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
29 Mar 2022 //
GLOBENEWSWIRE
Rani Tx Initiates Phase 1 Study of RT-102 Oral PTH for Osteoporosis
23 Mar 2022 //
GLOBENEWSWIRE
Rani Tx to Release Fourth Quarter and Full Year 2021 Financial Results
23 Mar 2022 //
GLOBENEWSWIRE
Rani Tx Unveils RaniPill Device; Reports 2021 Consolidated Financial Results
23 Feb 2022 //
GLOBENEWSWIRE
Rani Therapeutics Appoints Lisa Rometty to Board of Directors
07 Jan 2022 //
GLOBENEWSWIRE
